Ocular Therapeutix Company Profile
What is the competitive landscape for OCULAR THERAPEUTIX
OCULAR THERAPEUTIX has one approved drug.
There are five US patents protecting OCULAR THERAPEUTIX drugs.
Summary for Ocular Therapeutix
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Ocular Therapeutix
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 8,409,606 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 12,150,896 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 11,458,041 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 12,144,889 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 8,563,027 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ocular Therapeutix
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | 9,254,267 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ocular Therapeutix Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2427233 | ⤷ Start Trial |
| Canada | 2760704 | ⤷ Start Trial |
| European Patent Office | 3153194 | ⤷ Start Trial |
| China | 115768385 | ⤷ Start Trial |
| European Patent Office | 2396070 | ⤷ Start Trial |
| Canada | 2977830 | ⤷ Start Trial |
| Japan | 2015119979 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ocular Therapeutix Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1581193 | SPC/GB12/047 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
| 1429780 | SPC/GB12/058 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 1429780 | 13C0012 | France | ⤷ Start Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
